Johnson & Johnson is getting closer to seeking emergency FDA approval for its vaccine which could be a big boost to the supply. It even has some advantages over the others.
"Single dose, that's the big deal," said Dr. Jeffrey Carson with Rutgers Biomedical Health Sciences. "It's so much easier to manage vaccinating a population of patients if you only have to give one dose instead of two doses.
Carson is running the trials of the Johnson & Johnson vaccine on 45,000 people worldwide. He also added it doesn't have to be frozen at super low temperatures.
"We need multiple vaccines and I think this vaccine has the potential to have a profound impact on our ability to vaccinate a large number of people and to finally get the pandemic under control," Carson said.
As would be expected, anticipation for the vaccine is high to pick up the pace of immunization.
RELATED | Avoid preventive pain relievers before getting a COVID-19 vaccine: Experts
"Additional manufacturers like Johnson & Johnson will likely be approved in the coming weeks adding to our vaccine supply," said New Jersey Health Commissioner Judith Persichilli.
Johnson & Johnson could seek emergency use approval from the FDA by the end of next week.
Meanwhile, at NYU Langone Health, the AstraZeneca trial is nearing an end. Many trial participants are New Yorkers.
"This is our hope to have return of normalcy in the next year or two," said Dr. Tina Wu.
The trial, run by NYU Langone, features a vaccine that is cheaper than others at only $3 or $4 a dose. And massive amounts could be ready soon.
"And it's one that can be manufactured in high numbers, 3 billion doses they say they can make this year," said Dr. Mark Muligan.
Muligan said 35% of the participants are African-American, Hispanic and Native Americans. He says it is important to understand this is a worldwide push and there must be a global perspective.
"As long as there is virus somewhere, there's risk of more disease here," Muligan said.
The leaders of both the AstraZeneca and Johnson & Johnson trials are anxious to look at the trial data to make sure the vaccines are effective and get them to the market as soon as possible.
RELATED | What we know so far about COVID-19 variants worldwide
Fauci explains impact of COVID-19 variants on vaccine: 'We're paying very close attention to it'
MORE CORONAVIRUS COVID-19 COVERAGE
New Jersey COVID-19 Vaccine Tracker
New York City COVID-19 Vaccine Tracker
Find out if you are eligible and where you can go to get your vaccine
Do you have coronavirus symptoms?
Where to get tested in New York, New Jersey and Connecticut
WATCH: Eyewitness to a Pandemic
Centers for Disease Control and Prevention on coronavirus
Submit a News Tip or Question